KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Emergent BioSolutions (EBS) Accumulated Depreciation & Amortization (2016 - 2025)

Emergent BioSolutions' Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $95.8 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 11.95% year-over-year to $95.8 million; the TTM value through Dec 2025 reached $95.8 million, down 11.95%, while the annual FY2025 figure was $95.8 million, 11.95% down from the prior year.
  • Accumulated Depreciation & Amortization reached $95.8 million in Q4 2025 per EBS's latest filing, up from $72.3 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $143.3 million in Q4 2022 to a low of $25.4 million in Q1 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $75.4 million, with a median of $73.8 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 147.11% in 2021, then decreased 19.36% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $123.8 million in 2021, then rose by 15.75% to $143.3 million in 2022, then fell by 12.7% to $125.1 million in 2023, then decreased by 13.03% to $108.8 million in 2024, then fell by 11.95% to $95.8 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Accumulated Depreciation & Amortization are $95.8 million (Q4 2025), $72.3 million (Q3 2025), and $48.9 million (Q2 2025).